HERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that its Vice President of R&D, Teri Heiland, Ph.D., will be delivering an oral presentation on the company's LAMP-vax™ platform, along with one poster at the Skin Vaccination Summit in Lausanne, Switzerland on September 2-4.
The oral presentation, entitled, "'Immunization with ARA H-LAMP-vax peanut vaccine protects and blocks IgE-mediated anaphylaxis in a peanut allergic murine model," will be held on September 3, 2015 at 10:20 AM local time.
The poster, "Manufacture and Needle-Free, Intradermal Delivery of Antibiotic Free NTC RNA-Out™ LAMP-vax™ Plasmids,"was also co-authored by Dr. Heiland. The study demonstrates that intradermal administration of ITI's proprietary LAMP-vax formulation using a Biojector device showed improved generation of antibodies when compared to conventional injection.
"These presentations and posters represent significant advancement in the development LAMP-vax, particularly with regard to peanut allergies," said William Hearl, Ph.D., CEO of ITI. "As we continue to gather data regarding our technology and its application to treating peanut allergies, we are encouraged by what we are learning regarding the potential of our development programs. This work could allow for significant improvement in the lives of those who have suffered with allergies, particularly food allergies, with no viable solutions to date."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. LAMP was exclusively licensed from Johns Hopkins University and has been studied in various areas, including oncology and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:
- ASP 4070 (Formerly known as JRC-LAMP-vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
- ARA-LAMP-vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I studies in late 2015/early 2016;
- Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.
For more information about ITI and LAMP Technology, please visit www.immunomix.com.
CONTACT: Jules Abraham JQA Partners, Inc. 917-885-7378 email@example.comSource:Immunomic Therapeutics, Inc.